Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 151-160 of 171 (Search time: 0.003 seconds).
previous
1
...
13
14
15
16
17
18
next
Item hits:
Preview
Issue Date
Title
Author(s)
2012
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
Guilhot, F.
;
Hughes, T.
;
Cortes, J.
;
Druker, B.
;
Baccarani, M.
;
Gathmann, I.
;
Hayes, M.
;
Granvil, C.
;
Wang, Y.
2012
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
White, D.
;
Radich, J.
;
Soverini, S.
;
Saunders, V.
;
Frede, A.
;
Dang, P.
;
Cilloni, D.
;
Lin, P.
;
Mongay, L.
;
Woodman, R.
;
Manley, P.
;
Slader, C.
;
Kim, D.
;
Pane, F.
;
Martinelli, G.
;
Saglio, G.
;
Hughes, T.
2013
Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
Eadie, L.
;
Saunders, V.
;
Hughes, T.
;
White, D.
2011
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways
Tang, C.
;
Schafranek, L.
;
Watkins, D.
;
Parker, W.
;
Moore, S.
;
Prime, J.
;
White, D.
;
Hughes, T.
2016
ABCB1 Overexpression Is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines
Eadie, L.
;
Hughes, T.
;
White, D.
;
Eaves, C.
2009
Measuring minimal residual disease in chronic myeloid leukemia: Fluorescence in situ hybridization and polymerase chain reaction
Hughes, T.
;
Branford, S.
2010
Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo
Fraser, C.
;
Lousberg, E.
;
Guerin, L.
;
Hughes, T.
;
Brown, M.
;
Diener, K.
;
Hayball, J.
2005
Inhibition of c-fms by imatinib - Expanding the spectrum of treatment
Dewar, A.
;
Zannettino, A.
;
Hughes, T.
;
Lyons, A.
2015
Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia
Schafranek, L.
;
Nievergall, E.
;
Powell, J.
;
Hiwase, D.
;
Leclercq, T.
;
Hughes, T.
;
White, D.
2013
Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients
Ross, D.
;
O'Hely, M.
;
Bartley, P.
;
Dang, P.
;
Score, J.
;
Goyne, J.
;
Sobrinho-Simoes, M.
;
Cross, N.
;
Melo, J.
;
Speed, T.
;
Hughes, T.
;
Morley, A.
Discover
Author
61
Branford, S.
53
White, D.
35
Hochhaus, A.
22
Kantarjian, H.
22
Radich, J.
22
Saglio, G.
20
Kim, D.
20
Yeung, D.
19
Ross, D.
17
Cortes, J.
.
next >
Subject
90
Humans
65
Pyrimidines
64
Leukemia, Myelogenous, Chronic, B...
55
Piperazines
54
Benzamides
52
Imatinib Mesylate
42
Antineoplastic Agents
40
Fusion Proteins, bcr-abl
38
Protein Kinase Inhibitors
31
Male
.
next >
Date issued
1
2020 - 2022
97
2010 - 2019
64
2000 - 2009
9
1995 - 1999